Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 24,20 € (-0,45 %). Medianen er 23,59 € (-2,96 %).
| Køb |
15 |
| Behold |
5 |
| Sælg |
2 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Fitch upgrades Elanco after debt reduction and market share gains
Fitch Ratings has raised Elanco’s long-term issuer default rating from BB to BB+ and upgraded the rating on senior secured obligations to BBB-, with a stable outlook. The agency cites successful debt reductions of about $650 million since 2024, market share gains in the pet health segment, a broad product portfolio and improved cash‑flow generation. Fitch expects leverage to fall (gross leverage toward 3.0x by end‑2027), rising free cash flows through 2028 and EBITDA margins of around 21–22% after 2026. In the near term, freed cash flow is expected to be used primarily for debt repayment, while Elanco invests in product expansion, manufacturing and targeted acquisitions. » Mere på de.investing.com
Elanco receives FDA emergency approval for wound spray CLiK Extra against screw-worm fly
Elanco has received emergency approval from the FDA for the wound spray CLiK Extra, authorized to prevent infestations by the New World screw-worm fly in livestock and certain wild animals. The topical dicyclanil suspension may be used on sheep, cattle, goats, swine, camelids, captive deer, American bison, bighorn sheep and pronghorn, but it does not treat active infestations. Animals of the listed species must not be slaughtered for human consumption within 86 days after treatment; there is no established milk withdrawal period, and the product must not be used on milk-producing animals for human consumption. CLiK Extra will be available through usual veterinary distribution channels and the approval is valid for the duration of the federal emergency. » Mere på de.investing.com
Elanco: study shows Credelio Quattro kills black-legged ticks faster than competitors
Data in Parasites & Vectors show that Credelio Quattro reduces infections with black-legged ticks within 8 hours after treatment, both on day 0 and on day 28 of the dosing interval. Competing products Simparica Trio and NexGard Plus achieved significant reductions only after 12 and 24 hours, respectively, on day 28. Credelio Quattro is FDA-approved for Lyme prevention in dogs; common side effects in studies were vomiting and diarrhea, and the drug class has been linked to neurological effects. » Mere på de.investing.com
Elanco projects long-term growth on seven potential blockbusters and $25M venture fund
TD Cowen raised its price target on Elanco to $32 and cites seven potential blockbuster product launches, a diversified portfolio and pet retail leadership as drivers for projected revenue growth of over 5% and EPS growth of about 10% through 2032. Elanco announced Elanco Ventures, a corporate VC with a $25 million multi-year commitment to invest in Pre-Seed to Series A companies in animal health and One Health, expected to begin operations in late 2026 under Eric Steager. The initiatives aim to bolster future revenue and margin expansion alongside the company’s existing therapeutics and vaccines business. » Mere på finance.yahoo.com
Elanco launches $25 million venture fund for animal health
Elanco has announced Elanco Ventures, a corporate venture platform backed by a multi-year commitment of $25 million to support innovation in animal health. The fund will focus on early-stage investments (pre-seed to Series A) and is scheduled to launch in late 2026; Eric Steager will lead it. Elanco aims to use investments to advance therapeutics, technologies and partnerships under the One Health concept and the One Health Innovation District in Indianapolis. » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 1,12 mia. | 15,27 % |
| Bruttofortjeneste | 635,65 mio. | 22,89 % |
| Nettoresultat | 15,89 mio. | 154,85 % |
| EBITDA | 73,28 mio. | 51,69 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 12,15 mia. € |
Antal aktier | 499,83 mio. |
Højeste/laveste i 52 uger | 25,39 € - 17,60 € |
| Udbytte | Nej |
Beta | 1,72 |
P/E (PE Ratio) | -89,27 |
PEG (PEG Ratio) | 0,09 |
K/I (PB Ratio) | 2,02 |
P/S (PS Ratio) | 2,60 |
Virksomhedsprofil
Elanco Animal Health Incorporated er et dyresundhedsselskab, der udvikler, fremstiller og markedsfører produkter til husdyr og dyr på gårde. Selskabet tilbyder sygdomsforebyggende produkter til kæledyrs sundhed, såsom parasitmidler og vaccineprodukter, der beskytter kæledyr mod orm, lopper og flåter under mærkerne Seresto, Advantage, Advantix og Advocate; terapeutiske produkter til kæledyr til smerte, slidgigt, ørebetændelse, kardiovaskulære og dermatologiske indikationer hos hunde og katte under mærkerne Galliprant og Claro; vacciner, antibiotika, parasitmidler og andre produkter til brug i fjerkræ- og akvakulturproduktion samt ernæringsprodukter, herunder enzymer, probiotika og præbiotika; og en række vacciner, antibiotika, implantater, parasitmidler og andre produkter, der anvendes i produktion af drøvtyggere og svin under mærkerne Rumensin og Baytril. Selskabet sælger sine produkter til tredjepartsdistributører, dyrlæger og producenter af husdyr på gårde, herunder kød- og mælkeproducenter af kvæg samt svine-, fjerkræ- og akvakulturvirksomheder. Elanco Animal Health Incorporated blev grundlagt i 1954 og har hovedkvarter i Greenfield, Indiana.
| Navn | Elanco Animal Health |
| CEO | Jeffrey N. Simmons |
| Hjemsted | Indianapolis,
in USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Lægemidler |
| Børsnotering | 20.09.2018 |
| Medarbejdere | 9.650 |
Tickersymboler
| Børs | Symbol |
|---|---|
NYSE | ELAN |
Frankfurt | 5EA.F |
Düsseldorf | 5EA.DU |
München | 5EA.MU |